MedTrace Logo

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

NCT04902261 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2023-09-01

No results posted yet for this study

Summary

To evaluate the efficacy of Tislelizumab combined with Nab-paclitaxel and Gemcitabine in the treatment of recurrent pancreatic cancer

Conditions

  • Recurrent Pancreatic Cancer

Interventions

DRUG

Tislelizumab

Tislelizumab 200 mg every three weeks

DRUG

Nab paclitaxel

Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks

DRUG

Gemcitabine

Gemcitabine 1000mg/m2 on d1 and d8 every three weeks

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Gang Jin, Doctor · Changhai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2023-11-20
Completion
2023-11-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04902261 on ClinicalTrials.gov